RATIONALE: Macrophage accumulation in adipose tissue associates with insulin resistance and increased cardiovascular disease risk. We previously have shown that generation of reactive oxygen species and monocyte chemotactic factors after exposure of adipocytes to saturated fatty acids, such as palmitate, occurs via translocation of NADPH oxidase 4 into lipid rafts (LRs). The anti-inflammatory effects of apolipoprotein AI (apoAI) and high-density lipoprotein (HDL) on macrophages and endothelial cells seem to occur via cholesterol depletion of LRs. However, little is known concerning anti-inflammatory effects of HDL and apoAI on adipocytes. OBJECTIVE: To determine whether apoAI and HDL inhibit inflammation in adipocytes and adipose tissue, and whether this is dependent on LRs. METHODS AND RESULTS: In 3T3L-1 adipocytes, apoAI, HDL, and methyl-β-cyclodextrin inhibited chemotactic factor expression. ApoAI and HDL also disrupted LRs, reduced plasma membrane cholesterol content, inhibited NADPH oxidase 4 translocation into LRs, and reduced palmitate-induced reactive oxygen species generation and monocyte chemotactic factor expression. Silencing ATP-binding cassette A-1 abrogated the effect of apoAI, but not HDL, whereas silencing ATP-binding cassette G-1 or scavenger receptor B-1 abrogated the effect of HDL but not apoAI. In vivo, apoAI transgenic mice fed a high-fat, high-sucrose, cholesterol-containing diet showed reduced chemotactic factor and proinflammatory cytokine expression and reduced macrophage accumulation in adipose tissue. CONCLUSIONS: ApoAI and HDL have anti-inflammatory effects in adipocytes and adipose tissue similar to their effects in other cell types. These effects are consistent with disruption and removal of cholesterol from LRs, which are regulated by cholesterol transporters, such as ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1.
RATIONALE: Macrophage accumulation in adipose tissue associates with insulin resistance and increased cardiovascular disease risk. We previously have shown that generation of reactive oxygen species and monocyte chemotactic factors after exposure of adipocytes to saturated fatty acids, such as palmitate, occurs via translocation of NADPH oxidase 4 into lipid rafts (LRs). The anti-inflammatory effects of apolipoprotein AI (apoAI) and high-density lipoprotein (HDL) on macrophages and endothelial cells seem to occur via cholesterol depletion of LRs. However, little is known concerning anti-inflammatory effects of HDL and apoAI on adipocytes. OBJECTIVE: To determine whether apoAI and HDL inhibit inflammation in adipocytes and adipose tissue, and whether this is dependent on LRs. METHODS AND RESULTS: In 3T3L-1 adipocytes, apoAI, HDL, and methyl-β-cyclodextrin inhibited chemotactic factor expression. ApoAI and HDL also disrupted LRs, reduced plasma membrane cholesterol content, inhibited NADPH oxidase 4 translocation into LRs, and reduced palmitate-induced reactive oxygen species generation and monocyte chemotactic factor expression. Silencing ATP-binding cassette A-1 abrogated the effect of apoAI, but not HDL, whereas silencing ATP-binding cassette G-1 or scavenger receptor B-1 abrogated the effect of HDL but not apoAI. In vivo, apoAI transgenic mice fed a high-fat, high-sucrose, cholesterol-containing diet showed reduced chemotactic factor and proinflammatory cytokine expression and reduced macrophage accumulation in adipose tissue. CONCLUSIONS: ApoAI and HDL have anti-inflammatory effects in adipocytes and adipose tissue similar to their effects in other cell types. These effects are consistent with disruption and removal of cholesterol from LRs, which are regulated by cholesterol transporters, such as ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1.
Authors: Stephen J Nicholls; Pia Lundman; Jason A Harmer; Belinda Cutri; Kaye A Griffiths; Kerry-Anne Rye; Philip J Barter; David S Celermajer Journal: J Am Coll Cardiol Date: 2006-07-24 Impact factor: 24.094
Authors: Savitha Subramanian; Chang Yeop Han; Tsuyoshi Chiba; Timothy S McMillen; Shari A Wang; Antonio Haw; Elizabeth A Kirk; Kevin D O'Brien; Alan Chait Journal: Arterioscler Thromb Vasc Biol Date: 2008-01-31 Impact factor: 8.311
Authors: Ulrich Kintscher; Martin Hartge; Katharina Hess; Anna Foryst-Ludwig; Markus Clemenz; Martin Wabitsch; Pamela Fischer-Posovszky; Thomas F E Barth; Duska Dragun; Thomas Skurk; Hans Hauner; Matthias Blüher; Thomas Unger; Anna-Maria Wolf; Uwe Knippschild; Vinzenz Hombach; Nikolaus Marx Journal: Arterioscler Thromb Vasc Biol Date: 2008-04-17 Impact factor: 8.311
Authors: Andrew J Murphy; Kevin J Woollard; Anh Hoang; Nigora Mukhamedova; Roslynn A Stirzaker; Sally P A McCormick; Alan T Remaley; Dmitri Sviridov; Jaye Chin-Dusting Journal: Arterioscler Thromb Vasc Biol Date: 2008-07-10 Impact factor: 8.311
Authors: Chang Yeop Han; Savitha Subramanian; Christina K Chan; Mohamed Omer; Tsuyoshi Chiba; Thomas N Wight; Alan Chait Journal: Diabetes Date: 2007-06-11 Impact factor: 9.461
Authors: Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay Journal: Int Urol Nephrol Date: 2018-12-05 Impact factor: 2.370
Authors: Seth G Thacker; Abdalrahman Zarzour; Ye Chen; Mustafa S Alcicek; Lita A Freeman; Dennis O Sviridov; Stephen J Demosky; Alan T Remaley Journal: Immunology Date: 2016-08-28 Impact factor: 7.397
Authors: Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen Journal: J Biol Chem Date: 2020-02-25 Impact factor: 5.157